| 臺大學術典藏 |
2020-06-30T08:51:24Z |
Novel role of AMP-activated protein kinase signaling in cigarette smoke induction of IL-8 in human lung epithelial cells and lung inflammation in mice
|
Tang G.-J. ;Wang H.-Y. ;Wang J.-Y. ;Lee C.-C. ;Tseng H.-W. ;Wu Y.-L. ;Shyue S.-K. ;Tzong-Shyuan Lee ;Kou Y.R.; Tang G.-J.; Wang H.-Y.; Wang J.-Y.; Lee C.-C.; Tseng H.-W.; Wu Y.-L.; Shyue S.-K.; TZONG-SHYUAN LEE; Kou Y.R. |
| 臺大學術典藏 |
2020-06-30T08:51:23Z |
Wogonin promotes cholesterol efflux by increasing protein phosphatase 2B-dependent dephosphorylation at ATP-binding cassette transporter-A1 in macrophages
|
Chen C.-Y.;Shyue S.-K.;Ching L.-C.;Su K.-H.;Wu Y.-L.;Kou Y.R.;Chiang A.-N.;Pan C.-C.;Tzong-Shyuan Lee; Chen C.-Y.; Shyue S.-K.; Ching L.-C.; Su K.-H.; Wu Y.-L.; Kou Y.R.; Chiang A.-N.; Pan C.-C.; TZONG-SHYUAN LEE |
| 臺大學術典藏 |
2020-06-30T08:51:15Z |
Glucosamine attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling
|
Wu Y.-L.;Lin A.-H.;Chen C.-H.;Huang W.-C.;Wang H.-Y.;Liu M.-H.;Tzong-Shyuan Lee;Ru Kou Y.; Wu Y.-L.; Lin A.-H.; Chen C.-H.; Huang W.-C.; Wang H.-Y.; Liu M.-H.; TZONG-SHYUAN LEE; Ru Kou Y. |
| 臺大學術典藏 |
2020-06-27T06:40:15Z |
Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma
|
Lee Y.-L.;Ye Y.-L.;Yu C.-I.;Wu Y.-L.;Lai Y.-L.;Ku P.-H.;Hong R.-L.;Bor-Luen Chiang; Lee Y.-L.; Ye Y.-L.; Yu C.-I.; Wu Y.-L.; Lai Y.-L.; Ku P.-H.; Hong R.-L.; BOR-LUEN CHIANG |
| 臺大學術典藏 |
2020-06-17T03:00:44Z |
Intrathoracic goiter with superior vena cava syndrome and tracheal compression. A case report
|
Hao-Chih Tai;Wu Y.-L.;Lee J.-M.;Luh S.-P.;Lee Y.-C.; HAO-CHIH TAI; Wu Y.-L.; Lee J.-M.; Luh S.-P.; Lee Y.-C. |
| 臺大學術典藏 |
2020-06-11T06:42:10Z |
Improvement in radiation hardness of n-MOSFET's with gate oxides prepared by multiple N2O annealings
|
Wu, Y.-L.;Kuo, K.-M.;Hwu, J.-G.; Wu, Y.-L.; Kuo, K.-M.; Hwu, J.-G.; JENN-GWO HWU |
| 臺大學術典藏 |
2020-06-01T09:06:40Z |
Accountability and utilization of diabetes care from 2005 to 2014 in Taiwan
|
Chih-Yuan Wang;Wu Y.-L.;Sheu W.H.-H.;Tu S.-T.;Hsu C.-C.;Tai T.-Y.; CHIH-YUAN WANG; Wu Y.-L.; Sheu W.H.-H.; Tu S.-T.; Hsu C.-C.; Tai T.-Y. |
| 臺大學術典藏 |
2020-06-01T06:31:23Z |
Trends of mortality in diabetic patients in Taiwan: A nationwide survey in 2005–2014
|
Hung-Yuan Li;Wu Y.-L.;Tu S.T.;Hwu C.-M.;Liu J.-S.;Chuang L.-M.; HUNG-YUAN LI; Wu Y.-L.; Tu S.T.; Hwu C.-M.; Liu J.-S.; Chuang L.-M. |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
|
Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
|
Thongprasert S;Duffield E;Saijo N;Wu Y.-L;Chih-Hsin Yang;Chu D.-T;Liao M;Chen Y.-M;Kuo H.-P;Negoro S;Lam K.C;Armour A;Magill P;Fukuoka M.; Thongprasert S; Duffield E; Saijo N; Wu Y.-L; CHIH-HSIN YANG; Chu D.-T; Liao M; Chen Y.-M; Kuo H.-P; Negoro S; Lam K.C; Armour A; Magill P; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
|
Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer
|
Wu Y.-L;Park K;Soo R.A;Sun Y;Tyroller K;Wages D;Ely G;Chih-Hsin Yang;Mok T.; Wu Y.-L; Park K; Soo R.A; Sun Y; Tyroller K; Wages D; Ely G; CHIH-HSIN YANG; Mok T. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS)
|
Chih-Hsin Yang;Wu Y.-L;Chan V;Kurnianda J;Nakagawa K;Saijo N;Fukuoka M;Mcwalter G;Mccormack R;Mok T.S.K.; CHIH-HSIN YANG; Wu Y.-L; Chan V; Kurnianda J; Nakagawa K; Saijo N; Fukuoka M; McWalter G; McCormack R; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
|
Popat S;Mok T;Chih-Hsin Yang;Wu Y.-L;Lungershausen J;Stammberger U;Griebsch I;Fonseca T;Paz-Ares L.; Popat S; Mok T; CHIH-HSIN YANG; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
CHIH-HSIN YANG; Sequist L.V; Geater S.L; Tsai C.-M; Mok T.S.K; Schuler M; Yamamoto N; Yu C.-J; Ou S.H.I; Zhou C; Massey D; Zazulina V; Wu Y.-L.; Wu Y.-L.;Zazulina V;Massey D;Zhou C;Ou S.H.I;Yu C.-J;Yamamoto N;Schuler M;Mok T.S.K;Tsai C.-M;Geater S.L;Sequist L.V;Chih-Hsin Yang |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial
|
CHIH-HSIN YANG; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K.; Mok T.S.K.;Jiang H;Webster A;Shi X;Zhou J.-Y;Yoh K;Liu Y;Lee D.H;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Chih-Hsin Yang;Kim S.-W;Nakagawa K;Wu Y.-L;Soria J.-C; Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:26:53Z |
Impact of specific Epidermal Growth Factor Receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis
|
Chih-Hsin Yang;Gralla R.J;Gebski V;Links M;Pavlakis N;Rosell R;Mitsudomi T;Zhou C;Inoue A;Lord S.J;Ding P.N;Wu Y.-L;Lee C.K; Lee C.K; Wu Y.-L; Ding P.N; Lord S.J; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla R.J; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials
|
Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases
|
Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu Y.-L.;Shah R;Mok T;Hirsh V;O'Byrne K;Zhou C;Yamamoto N;Sequist L.V;Chih-Hsin Yang;Schuler M; Schuler M; CHIH-HSIN YANG; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L. |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
|
Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
|
Syrigos K; van Meerbeeck J.P; van Zandwijk N; Chih-Hsin CHIH-HSIN YANG; Zhou C; Vokes E.; Vokes E.;Zhou C;Chih-Hsin Yang;Van Zandwijk N;Van Meerbeeck J.P;Syrigos K;Smit E.F;P?rol M;Papotti M;Novello S;Mornex F;Moniuszko M;Marabelle A;Huber R.M;Garrido P;Fennell D;Felip E;Crin? L;Brustugun O.T;Wu Y.-L;Reck M;Peters S;Nicolson M;Nakagawa K;Gray J.E;Dingemans A.-M.C;Manegold C; Manegold C; Dingemans A.-M.C; Gray J.E; Nakagawa K; Nicolson M; Peters S; Reck M; Wu Y.-L; Brustugun O.T; Crinò L; Felip E; Smit E.F; Pérol M; Papotti M; Fennell D; Garrido P; Huber R.M; Marabelle A; Moniuszko M; Mornex F; Novello S |
